Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A Population-based Study of Immunotherapy-related Toxicities in Lung Cancer

Clinical Lung Cancer(2020)10.1016/j.cllc.2020.04.003Source: DataRank Database

A Population-based Study of Immunotherapy-related Toxicities in Lung Cancer is a research paper published in Clinical Lung Cancer (2020). On theSindex it has a DataRank of 0. It has been cited 42 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access42 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 2.05)OA: greenTopics (50)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Lindsey R. Sangaralingham ORCID,Henry J. Henk ORCID,Nilay D. Shah ORCID,Irbaz Bin Riaz ORCID,Aaron S. Mansfield ORCID

Live enrichment

PubMed:32446852 PMC:PMC7486993 OpenAlex:https://openalex.org/W3016407352

National Institutes of Health

Grant: K12 CA 90628

National Institutes of Health

Grant: P30CA015083

NCI NIH HHS

Grant: K12 CA090628

National Institutes of Health

Grant: 5K12CA090628-25

Paul Calabresi Program in Clinical/Translational Research at Mayo Clinic

National Institutes of Health

Grant: 3P30CA015083-37S2

Mayo Comprehensive Cancer Center Grant

National Institutes of Health

FWCI

2.05

Citation Percentile

0.9%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

greenLicense: Elsevier TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7486993

publisherhttps://api.elsevier.com/content/article/PII:S1525730420301029?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1525730420301029?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.cllc.2020.04.003

Fields of Study

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsDrug-Induced Adverse Reactions03 medical and health sciences0302 clinical medicine

MeSH Terms

Immune Checkpoint InhibitorsAgedCarcinoma, Non-Small-Cell LungFemaleFollow-Up StudiesHumansImmunotherapyLung NeoplasmsMaleMiddle AgedMinnesotaPrognosisRetrospective StudiesIncidenceSurvival RateDrug-Related Side Effects and Adverse Reactions

Keywords

MedicineLung cancerImmunotherapyOncologyPopulationCancerCancer immunotherapyInternal medicineIntensive care medicineEnvironmental healthPD-L1PneumonitisImmune-related Adverse EventsHypophysitisMaleLung NeoplasmsDrug-Related Side Effects and Adverse ReactionsIncidenceMinnesotaMiddle AgedPrognosisSurvival RateCarcinoma, Non-Small-Cell LungHumansFemaleImmune Checkpoint InhibitorsAgedFollow-Up StudiesRetrospective Studies

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being